Safety of Abatacept in Rheumatoid Arthritis with Serologic Evidence of Past or Present Hepatitis B Virus Infection

Arthritis Care and Research

Volumn 68, Issue 6, 2016, Pages 738-743

  Padovan, Melissa ^a   Filippini, Matteo ^b   Tincani, Angela ^b   Lanciano, Elisabetta ^c   Bruschi, Eleonora ^d   Epis, Oscar ^d   Garau, Pietro ^e   Mathieu, Alessandro ^e   Celletti, Eleonora ^f   Giani, Leopoldo ^g   Tomietto, Paola ^h   Atzeni, Fabiola ⁱ   Sarzi Puttini, Piercarlo ⁱ   Zuliani, Francesca ^j   De Vita, Salvatore ^j   Trotta, Francesco ^a   Grilli, Anastasio ^a   Puoti, Massimo ^d   Govoni, Marcello ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c POLICLINICO   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

^g Ospedale Civile   (Italy)

^h UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j UNIVERSITY OF UDINE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADEFOVIR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HEPATITIS C ANTIBODY; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TENOFOVIR; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; ITALIAN (CITIZEN); LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEROLOGY; SKIN ULCER; URINARY TRACT INFECTION; VERY ELDERLY; VIRUS REACTIVATION; VIRUS REPLICATION; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; VIRUS ACTIVATION;

ABATACEPT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HEPATITIS B; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 84969949525     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22786     Document Type: Article

References (44)

1. World Health Organization. Hepatitis B fact sheet 2014. URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
2. Charpin C, Guis S, Colson P, Borentain P, Mattei JP, Alcaraz P, et al., Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11: R179.
3. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, et al., Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010; 62: 749-54.
4. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, Lopez-Roses L, Brito-Zeron P, Perez-de-Lis M, et al., Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-71.
5. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al., Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 16-23.
6. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al., Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-64.
7. Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K, et al., Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen negative cases. J Rheumatol 2011; 38: 2209-14.
8. Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, et al., Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012; 4: 37-45.
9. Lee YH, Bae SC, Song GG., Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013; 31: 118-21.
10. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, et al., HBV reactivation in patients treated with antitumor necrosis factor-α (TNF-α) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int J Rheumatol 2014; 2014: 926836.
11. Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marignani M, Stroffolini T, et al., Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Eur J Intern Med 2014; 25: 482-4.
12. Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T., Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol 2013; 5: 612-20.
13. Shouval D, Shibolet O., Immunosuppression and HBV reactivation. Semin Liver Dis 2013; 33: 167-77.
14. Lunel-Fabiani F, Masson C, Ducancelle A., Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine 2014; 81: 478-84.
15. Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, et al., Rituximab administration and reactivation of HBV. Hepat Res Treat 2010; 2010: 182067.
16. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al., Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2: CD008794.
17. De Nard F, Todoerti M, Grosso G, Monti S, Breda S, Rossi S, et al., Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs. World J Hepatol 2015; 7: 344-61.
18. Droz N, Gilardin L, Cacoub P, Berenbaum F, Wendling D, Godeau B, et al., Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken) 2013; 65: 1504-14.
19. Davis PM, Nadler SG, Stetsko DK, Suchard SJ., Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol 2008; 126: 38-47.
20. Thio CL, Mosbruger TL, Kaslow RA, Karp CL, Strathdee SA, Vlahov D, et al., Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004; 78: 11258-62.
21. Carroll MB., The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin Biol Ther 2011; 11: 533-44.
22. Kim PS, Ho GY, Prete PE, Furst DE., Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken) 2012; 64: 1265-8.
23. Germanidis G, Hytiroglou P, Zakalka M, Settas L., Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 2012; 56: 1420-1.
24. Fanouriakis A, Vassilopoulos D, Repa A, Boumpas DT, Sidiropoulos P., Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology (Oxford) 2014; 53: 195-6.
25. De Nard F, Todoerti M, Grosso V, Rossi S, Caporali R, Montecucco C., Safety of the newer biological DMARDs, tocilizumab and abatacept, in rheumatoid arthritis patients with a history of HBV infection: a real life experience. Proceedings of the European League Against Rheumatism Congress; 2014 June 11-14; Paris, France.
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
27. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
28. EASL Clinical Practice Guidelines. Management of chronic hepatitis B. J Hepatol 2012; 57: 167-85.
29. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al., Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20.
30. Winthrop KL, Calabrese LH., Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis 2011; 70: 1701-3.
31. Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, et al., TNFα antagonist therapy and safety monitoring. Joint Bone Spine 2011; 78: 15-185.
32. Giemza A, Olesinska M, Swierkocka K, Szewczyk E, Haladyj E., Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatol Int 2015; 35: 385-92.
33. Pham T, Bachelez H, Berthelot JM, Blacher J, Claudepierre P, Constantin A, et al., Abatacept therapy and safety management. Joint Bone Spine 2012; 79: 3-84.
34. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al., American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
35. Rahier JF., Prevention and management of infectious complications in IBD. Dig Dis 2012; 30: 408-14.
36. Runyon BA., Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-97.
37. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, et al., Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013; 72 Suppl 2: ii2-34.
38. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013; 0: 1-18.
39. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al., EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-22.
40. Xu H, Zhao M, He J, Chen Z., Association between cytotoxic T-lymphocyte associated protein 4 gene +49 A/G polymorphism and chronic infection with hepatitis B virus: a meta-analysis. J Int Med Res 2013; 41: 559-67.
41. Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, et al., Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011; 53: 1494-503.
42. Zhong B, Huang MP, Yin GQ, Gao X., Effects of costimulation on intrahepatic immunopathogenesis in patients with chronic HBV infection. Inflamm Res 2014; 63: 217-29.
43. Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M., Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012; 12: 193-207.
44. Vigano M, Mangia G, Lampertico P., Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opin Biol Ther 2014; 14: 1019-31.